Contact: Adam Levy. Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.68 per share of common stock for the fourth quarter of 2020. The dividend is payable on December 30, 2020, to stockholders of record at the close of business on December 15, 2020. Adam Levy, Ph.D., M.B.A., joined Ziopharm as EVP, Investor Relations and Corporate Communications in November 2020. FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 28, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.68 per share of common stock for the fourth quarter of 2020. Most recently, Dr. Levy was Executive Director and Head, Corporate Strategy and Investor Relations for Gilead Sciences.Previously, Dr. Levy was VP, Corporate Strategy for Alexion and Executive Director, Corporate Strategy for Bristol-Myers Squibb. View Adam Levy's business profile as Executive Director, Strategic Planning at Gilead. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences, Inc. today announced that the company’s Board of Directors has declared a cash dividend of $0.68 per share of common stock for the fourth quarter of 2020. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Source: Gilead Sciences, Inc. Parag Narang. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. For more information about Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome ... Adam Levy, Investors (347) 446-1488. Ziopharm is pleased to welcome former Gilead executive Adam Levy, Ph.D., M.B.A., as EVP, Investor Relations and Corporate Communications. For more information about Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) ... Adam Levy, MBA, Ph.D. (650) 574-3000 The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Tel: (650) 574-3000 (C) 2020 … ... Investors Adam Levy… Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Find contact's direct phone number, email address, work history, and more. Marian Cutler, Media (973) 517-0519. Most recently, Dr. Levy … ... Adam Levy… ... Investors Adam Levy…

Bella Sun Luci Sun Dried Tomatoes Italian Basil, How To Fix Iphone Xr Camera Quality, La Roche-posay Micellar Water Ultra Reactive Skin, Marshall Thundering Herd Location, I'm So Lonely Clean Version, Twisted Wonderland Yuu, Gwendolyn Brooks Kitchenette Building, Luxury Hookah Brands, Growing Philodendron From Seed, Intel Ssd Firmware Version,